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ABSTRACT
Objectives: To develop evidence-based EULAR recom-
mendations for cardiovascular (CV) risk management in
patients with rheumatoid arthritis (RA), ankylosing
spondylitis (AS) and psoriatic arthritis (PsA).
Methods: A multidisciplinary expert committee was
convened as a task force of the EULAR Standing
Committee for Clinical Affairs (ESCCA), comprising 18
members including rheumatologists, cardiologists, inter-
nists and epidemiologists, representing nine European
countries. Problem areas and related keywords for
systematic literature research were identified. A sys-
tematic literature research was performed using MedLine,
Embase and the Cochrane library through to May 2008.
Based on this literature review and in accordance with the
EULAR’s ‘‘standardised operating procedures’’, the multi-
disciplinary steering committee formulated evidence-
based and expert opinion-based recommendations for CV
risk screening and management in patients with
inflammatory arthritis.
Results: Annual CV risk assessment using national
guidelines is recommended for all patients with RA and
should be considered for all patients with AS and PsA.
Any CV risk factors identified should be managed
according to local guidelines. If no local guidelines are
available, CV risk management should be carried out
according to the SCORE function. In addition to
appropriate CV risk management, aggressive suppression
of the inflammatory process is recommended to further
lower the CV risk.
Conclusions: Ten recommendations were made for CV
risk management in patients with RA, AS and PsA. The
strength of the recommendations differed between RA on
the one hand, and AS and PsA, on the other, as evidence
for an increased CV risk is most compelling for RA.
Providing recommendations for monitoring and/or
management and/or treatment of musculoskeletal
disorders is one of the goals of the EULAR Standing
Committee for Clinical Affairs (ESCCA).1
Obviously, management of patients with inflam-
matory arthritis focuses not on cardiovascular
(CV) morbidity and mortality. However, standar-
dised mortality ratios (SMRs) are raised and the
majority of premature deaths are attributable to
CV disease.2–4 CV morbidity is also enhanced and
there is an increased prevalence of all stages of
atherogenesis, from endothelial dysfunction to
increased thickness and plaque in carotid arteries,
to fatal and non-fatal myocardial infarction and
stroke.5–10 Moreover, the excess CV burden persists
after adjustment for traditional CV risk factors.11 12
Evidence is best documented for rheumatoid
arthritis (RA), but patients with ankylosing
spondylitis (AS) and psoriatic arthritis (PsA) also
appear to be at increased CV risk. Accordingly,
available evidence supports inflammatory arthritis
as an independent CV risk factor, and CV risk
screening and management is therefore needed.
CV risk screening and management strategies have
been developed for the general population and are
based on CV risk score calculators, such as the
Framingham score (often used in the United States)
and the Systematic Coronary Risk Evaluation
(SCORE) model (often used in Europe).13 14
Traditional risk factors integrated in these models
are age, gender, smoking, blood pressure and lipid
(cholesterol and high-density lipoprotein-cholesterol
(HDL-c)) levels. Risk estimates are based on informa-
tion from the general population but the accuracy of
these models has not been adequately evaluated in
inflammatory arthritis, such as RA, AS and PsA.15
Hence, we summarised and evaluated currently
available literature according to the EULAR standar-
dised operating procedures, to provide evidence-based
EULAR recommendations for CV risk management
in patients with inflammatory arthritis.
Participants and objectives
A multidisciplinary guideline development com-
mittee was commissioned by ESCCA. The steering
committee comprised 18 members including rheu-
matologists, cardiologists, internists and epidemiol-
ogists, representing nine European countries. The
objectives were (a) to identify and critically
appraise evidence for specific CV interventions
aimed at lowering the CV risk in RA; (b) to develop
EULAR recommendations on the basis of the
presented literature search for CV risk assessment
in patients with RA, AS and PsA; (c) to determine
future research goals.
Systematic literature search
A systematic search of literature published between
January 1966 and May 2008 was undertaken using
Recommendations
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Medline, Embase and the Cochrane library databases (Appendix 1,
supplementary online file). The search consisted of two or three
components: (a) the rheumatic disease in Medical Subject
Headings (MeSH) or title abstract terms; (b) MeSH or title
abstract terms for each CV traditional risk factor—that is, age,
gender, cholesterol, blood pressure and smoking; (c) the MeSH or
title abstract term ‘‘cardiovascular disease’’ was added to the
search with age and gender in order to increase specificity. We
only included key articles supporting issued recommendations.
Selected articles were screened for eligibility by two investigators
(MJLP and MTN).
Experts’ consensus
When the literature search was completed, 10 concept
recommendations were formulated. These were discussed
within the steering committee until consensus was reached.
Categorising evidence
The grading of the recommendations was based on the
methodological strength of the underlying literature, which
was categorised according to standard guidelines (supplemen-
tary online tables). Obviously, the level of evidence is far greater
for RA than for AS and PsA and therefore, the strength of
recommendations is higher for patients with RA. Hence, for AS
and PsA our recommendations should be seen as points to
consider rather than definitive recommendations.
RESULTS
Recommendations
Table 1 lists the recommendations for CV management in RA,
PsA and AS.
1. RA should be regarded as a condition associated with higher risk for
CV disease. This may also apply to AS and PsA, although the evidence
base is less. The increased risk appears to be due to both an increased
prevalence of traditional risk factors and the inflammatory burden
The overall SMR for RA is approximately two and numerous
reports have demonstrated that the excess mortality is mostly due
to CV disease.1 2 It is unclear whether survival for patients with
RA has improved over recent years as conflicting observations
have been published.16–19 The absolute risk of CV death is highest
for elderly, male patients with RA, whereas the relative risk is
highest for young female patients with RA.20 21 CV morbidity is
also enhanced and the magnitude of CV risk in RA may equal the
CV risk in patients with type 2 diabetes.22 Traditional CV risk
factors—that is, hypertension, dyslipidaemia and smoking,
probably occur more frequently, but the evidence is not uniform
and adequate studies are lacking.23–27 Traditional CV risk factors,
however, only account partially for the excess CV risk. The key
feature explaining the increased CV risk seems to be inflamma-
tion, as it, on the one hand, has an important role in different
stages of atherogenesis, and, on the other, accentuates established
CV risk factors.28–31 Moreover, there is strong evidence showing
that chronic inflammatory markers are independently associated
with CV mortality and morbidity in RA.31–35 Information about
mortality rates in AS or PsA compared with the general
population is limited, but reported SMRs are increased and range
from 1.5 to 1.9, and similar to RA, the excess mortality is
predominantly due to CV disease.4 Presently, evidence for an
increased CV risk in these patients is emerging and therefore AS
and PsA should also be considered as CV risk factors.
2. Adequate control of disease activity is necessary to lower the CV
risk (best evidence for anti-tumour necrosis factor treatment and
methotrexate treatment)
Studies investigating the association between inflammation and
atherosclerosis, using surrogate markers for CV disease, such as
Table 1 The 10 recommendations for cardiovascular (CV) risk management in rheumatoid arthritis (RA),
psoriatic arthritis (PsA) and ankylosing spondylitis (AS)
Recommendations
Level of
evidence
Strength of
recommendation
1. RA should be regarded as a condition associated with higher risk for
CV disease. This may also apply to AS and PsA, although the evidence
base is less. The increased risk appears to be due to both an increased
prevalence of traditional risk factors and the inflammatory burden
2b–3 B
2. Adequate control of disease activity is necessary to lower the CV risk 2b–3 B
3. CV risk assessment using national guidelines is recommended for all patients
with RA and should be considered annually for all patients with AS and PsA.
Risk assessments should be repeated when antirheumatic treatment has
been changed
3–4 C
4. Risk score models should be adapted for patients with RA by introducing
a 1.5 multiplication factor. This multiplication factor should be used when
the patient with RA meets two of the following three criteria:
3–4 C
– Disease duration of more than 10 years
– RF or anti-CCP positivity
– Presence of certain extra-articular manifestations
5. TC/HDL cholesterol ratio should be used when the SCORE model is used 3 C
6. Intervention should be carried out according to national guidelines 3 C
7. Statins, ACE inhibitors and/or AT-II blockers are preferred treatment options 2a–3 C-D
8. The role of coxibs and most NSAIDs in CV risk is not well established
and needs further investigation. Hence, we should be very cautious about
prescribing them, especially for patients with a documented CV disease or
in the presence of CV risk factors
2a–3 C
9. Corticosteroids: use the lowest dose possible 3 C
10. Recommend smoking cessation 3 C
ACE, angiotensin-converting enzyme; anti-CCP, anti-cyclic citrullinated peptide; AT-II, angiotensin II; coxibs, cyclo-oxygenase-2
inhibitors; HDL, high-density lipoprotein; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; SCORE, Systematic
Coronary Risk Evaluation; TC, total cholesterol.
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intima medial thickness, confirm the important role of
inflammation in accelerating atherosclerosis.36–38 These results
illustrate the interplay between inflammation and atherosclero-
sis in inflammatory arthritis and underline the importance of a
more aggressive approach for treatment of inflammatory
arthritis. Early and effective antirheumatic treatment, such as
tumour necrosis factor blockers and methotrexate (MTX), has
been shown to be independently associated with a lower CV
risk.39–45 Effective treatment may also result in improved
physical activity, subsequently leading to a decreased risk of
hypertension, obesity and diabetes, all important determinants
of CV disease. Moreover, MTX may induce hyperhomo-
cysteinaemia through a depletion of folic acid levels.46
Hyperhomocysteinaemia has toxic effects on the endothelium,
is procoagulant and therefore a CV risk factor.47–49 Hence, folic
acid is advised as it prevents MTX-induced hyperhomo-
cysteinaemia, albeit the ultimate effect on CV risk in RA is
unknown.50 51
3. CV risk assessment using national guidelines is recommended for
all patients with RA and should be considered annually for all patients
with AS and PsA. Risk assessments should be repeated when
antirheumatic treatment has been changed (in absence of national
guidelines the SCORE function model is recommended)
As noticed earlier, CV risk assessment is recommended for all
patients with RA and should be considered for all patients with
AS and PsA. In this regard, to ensure sufficient take up of CV
risk assessment, we have recommended that all patients receive
an annual CV risk assessment but we recognise that in patients
with low CV risk and inactive disease a lower frequency of
assessment—for example, every 2 or 3 years, could be adopted.
Additionally, CV risk assessment should be reconsidered during
the disease course, as inflammation as well as antirheumatic
treatment may alter CV risk factors, but again this is only
necessary in patients already at increased CV risk. Hence, the
treatment and follow-up plan should be determined on an
individual basis and with regard to risk profile, morbidity,
comorbidity and the patient’s preferences. It should also be
noted that CV risk assessment can be easily incorporated into a
routine visit to monitor RA by addition of the determination of
non-fasting lipids (cholesterol and HDL-c) to routine laboratory
tests and by measurement of blood pressure.
4. Risk score models should be adapted for patients with RA by
introducing a 1.5 multiplication factor. This multiplication factor
should be used when the patient with RA meets two of the following
three criteria:
cDisease duration of more than 10 years
cRF or anti-CCP positivity
cPresence of certain extra-articular manifestations
Since traditional CV risk factors are already included in existing
CV risk score models, it is important to identify other factors
associated with an increased CV risk in RA. One important
predictor is disease duration, which is illustrated by numerous
reports observing that excess mortality increases with a longer
disease duration.16 52 A meta-analysis showed a mean SMR of
1.2 for inception cohorts (,2 years’ disease duration) compared
with a mean SMR of 1.9 for established disease.53 Other
prognostic CV disease markers are rheumatoid factor (RF) or
anti-cyclic citrullinated peptide (anti-CCP) positivity.33 54–58
Finally, patients with severe disease (eg, those with extra-
articular manifestations) have an increased risk for CV
disease.56 58–60 Therefore, it is recommended that the derived
CV risk estimate should be multiplied by 1.5 if at least two of
the following criteria are present: disease duration of more than
10 years, RF and/or anti-CCP positivity, presence of severe
extra-articular manifestations.61 Since available comparative
studies did not adequately adjust for important confounders
(social class, physical activity and others), and in addition, few,
if any, adjusted for all established CV risk factors using
continuous data, it is possible that the excess CV risk in
inflammatory arthritis, over and above traditional risk factors,
has been overestimated. Hence, a conservative approach—that
is, a multiplication factor of 1.5 (rather than 2.0), has been
chosen on the basis of the evidence from observational SMR
reporting studies as well as expert opinion. At present, this
multiplication factor should only be used for patients with RA.
5. Total cholesterol/HDL cholesterol ratio should be used when the
SCORE model is used
Dyslipidaemia, particularly low levels of HDL-c, and high levels
of total cholesterol (TC), low-density lipoprotein cholesterol
(LDL-c) and triglycerides are associated with an increased CV
risk in the general population.62–64 Particularly, the TC/HDL-c
ratio is an important prognostic indicator for future CV
disease.64 Patients with inflammatory arthritis, particularly
those with active disease, have low HDL-c levels resulting in a
higher—that is, unfavourable, TC/HDL-c ratio, and high
triglyceride levels.65–67 Moreover, it appears that these unfavour-
able lipid changes may already be present at least 10 years before
the onset of RA.68 Hence, an unfavourable lipid profile may
contribute to the increased CV risk in patients with inflamma-
tory arthritis. By contrast, disease-modifying antirheumatic
drugs (including initial corticosteroids) appear to have beneficial
effects on the lipid profile in patients with early active RA—that
is, an increase of TC but a more pronounced increase of HDL-c
resulting in a lower (more favourable) TC/HDL-c ratio.69–71
Tumour necrosis factor blockers are also associated with a
transient increase of TC and HDL-c, mostly accompanied with
improvement of the TC/HDL-c ratio, during the first few
months of the treatment.72–74 Thereafter the results become
divergent and this might be due to differences in disease
activity, (changes of) co-medication, particularly corticosteroids,
dietary intake and physical activity.75–77 Hence, future studies
should appropriately examine these potential confounders to
reach valid conclusions. In the meantime, it appears that the
ratio of TC to HDL-c is the most stable marker of lipid-
associated risk in RA.
6. Intervention should be carried out according to national guidelines.
CV risk assessment differs from country to country. The
SCORE model is used in some countries, whereas in other
countries the Framingham or no model is used. In addition, risk
factors included in the models as well as treatment thresholds
for initiation of cardioprotective agents or treatment goals may
differ. As there is no evidence to indicate preference of one
model above the other (and likewise treatment thresholds), risk
assessment and management should be carried out according to
national guidelines. If there are no local guidelines on the risk
model to use then, the use of SCORE (see ‘‘Example’’ below) is
advised. Commonly used treatment thresholds are a systolic
blood pressure of 140 mm Hg and an LDL-c level of 2.5 mmol/l.
As evidence describing the effect of cardioprotective agents on
CV end points in inflammatory arthritis is lacking, we have to
extrapolate evidence from the general population in order to
guide clinicians in their decision on the use of cardioprotective
Recommendations
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agents in inflammatory arthritis. This means that modification
and or specific intervention, such as antihypertensive agents or
statins, should be the same as in the general population and
should be initiated according to national guidelines. This
statement is supported by a great number of observational
studies as well as expert consensus.
7. Statins, ACE-inhibitors and/or angiotensin II blockers are preferred
treatment options due to their potential anti-inflammatory effects
Intervention trials with statins and/or antihypertensive agents
and CV end points in RA have not been published thus far.
However, it is very unlikely that the effect of statins and/or
antihypertensive agents would be attenuated. The effect might
be more pronounced as statins and ACE inhibitors possess
potential anti-inflammatory properties, which may be clinically
significant in the context of inflammatory disorders. A
randomised controlled trial of atorvastatin in RA demon-
strated,78 in addition to a moderate decrease in disease activity,
a significant reduction in TC and LDL-c in statin-treated
patients with RA. The observed changes were at least
equivalent to expected reductions in TC and LDL-c in non-RA
subjects given atorvastatin.79 Since reduction in LDL-c is the
best simple predictor of relative CV risk reduction, it is
conceivable that at least an equivalent risk reduction will be
achieved.80–84 Similarly to statins, ACE inhibitors and angioten-
sin II (AT-II) blockers may also have a favourable effect on
inflammatory markers and endothelial function in RA.83 85–87
Hence, these agents are preferred, when antihypertensive agents
are indicated. Nevertheless, future research with CV end points
is needed to examine these questions more profoundly.
8. The role of cyclo-oxygenase-2 inhibitors and most non-steroidal
anti-inflammatory drugs in CV risk is not well established and needs
further investigation. Hence, we should be very cautious about
prescribing them, especially for patients with a documented CV
disease or in the presence of CV risk factors
Non-steroidal anti-inflammatory drugs (NSAIDs), and cyclo-
oxygenase-2 inhibitors (coxibs) are associated with an increased
CV risk.88 89 The overall effects of NSAIDs and coxibs on CV risk
are difficult to ascertain, as on the one hand, most of them, but
not all, have prothrombotic effects due cyclo-oxygenase 2
inhibition, and on the other hand, these agents improve
mobility of patients with RA, which might counterbalance
the prothrombotic effects.90 91 Moreover, a possible interaction
between some NSAIDs and aspirin has been reported as some
NSAIDs may impair aspirin’s antiplatelet function.92–96
Conclusive evidence is not yet available and therefore the
potential atherothrombotic risk of any NSAID or COXIB must
be taken into account when prescribing these drugs according to
recommendations from the European Medicines Agency,
especially in patients with documented CV disease or in the
presence of CV risk factors.
9. Corticosteroids: use the lowest dose possible
Corticosteroids are commonly used in rheumatic patients and
may influence the CV risk in two competing ways. On the one
hand, corticosteroids could enhance CV risk owing to their
potentially deleterious effects on lipids, glucose tolerance,
insulin production and resistance, blood pressure and obe-
sity.95–97 On the other hand, corticosteroids may actually
decrease the risk of atherosclerosis and CV disease by suppres-
sing inflammation, which paradoxically may improve glucose
intolerance and dyslipidaemia.98 99 Owing to these opposing
effects of corticosteroids on CV risk, it is important to take into
account rheumatic disease features as well as traditional CV risk
factors when considering the net effects of corticosteroids on
CV risk.100 Furthermore, CV risk is higher in patients treated
with long-term high doses compared with low doses of
corticosteroids.101
Altogether, there is no clear evidence that low-dose cortico-
steroids contribute significantly to the enhanced CV risk in
inflammatory arthritis, in contrast to high-dose corticosteroids.
Corticosteroids rapidly and effectively suppress inflammation in
RA and their use might be justified for short-term treatment—
for example, for ‘‘bridging therapy’’ in the period between
initiation and response to disease-modifying antirheumatic drug
treatment, although the debate appears not to be settled yet.
Therefore, a conservative approach was chosen, recommending
the use of the lowest dose for the shortest period possible.
10. Recommend smoking cessation
At present, although there is no strong evidence that smoking
has a key role in the excess CV risk in RA, it clearly contributes
to a higher absolute risk in individual patients. Hence,
Box 1 Research agenda
c Information about the effects of lipid-lowering and
antihypertensive agents on cardiovascular (CV) risk in
inflammatory arthritis is lacking. Randomised controlled trials
are needed to examine this question and some long-term trials
are currently being conducted. Additional information is
needed about the number needed to harm and the number
needed to treat with respect to interaction between lipid-
lowering agents and/or antihypertensive agents and
antirheumatic treatment in inflammatory arthritis.
c The search strategy did not include information about lifestyle
modification—for example, weight control and physical
activity. Lifestyle should be considered as a major CV risk
factor. Modest reduction in weight or improvement in physical
activity may significantly reduce the CV risk. Hence, lifestyle
modification should be given to all patients. Briefly, smoking
cessation, weight reduction and exercise are pivotal (evaluating
the effect of lifestyle modification on the CV risk in inflammatory
arthritis was added to the future research agenda).
c The contribution of other CV risk factors like stress,
educational and social background towards excess CV disease
in inflammatory rheumatic conditions is presently unknown
and needs to be established.
c Accurate CV risk assessment may be more difficult in
inflammatory arthritis as the relative role of traditional risk
factors contributing to the increased CV risk is unclear.
Therefore, studies evaluating the efficacy and applicability of
different CV risk scores are needed in inflammatory arthritis.
c Probably, existing risk score models underestimate risk in
women. This may be important particularly in rheumatoid
arthritis, where there is a female sex preponderance, and
warrants further investigation.
c As evidence for ankylosing spondylitis and psoriatic arthritis is
emerging we will revise the guidelines accordingly within 3 years.
c Our recommendation for the multiplication factor of 1.5 is
derived mainly from relevant standardised mortality ratios and,
because information from large-scale prospective cohort
studies is lacking. Obviously, this value should be re-examined
in due course when better evidence emerges.
Recommendations
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rheumatologists are strongly recommended to advise and help
their patients to stop smoking, wherever possible, using best
evidence-based methods.
RESEARCH AGENDA
The committee composed a research agenda to further optimise
CV risk management (box 1). As evidence for AS and PsA is
emerging, we will re-evaluate the evidence for AS and PsA and
aim to revise the guidelines within 3 years. We acknowledge
that our recommendations for the multiplication factor of 1.5
are derived mainly from relevant SMRs, which strictly speaking
is not ideal. However, there is a scarcity of prospective cohorts
to enable the more usual approach in defining multiplication
factors. Therefore, the arbitrary but conservative threshold of
1.5 has been chosen. Interestingly, data from a recent UK
general practitioner study provides additional support for a
multiplication factor of around 1.5.102 Obviously, this value can
be re-examined in due course when better evidence emerges.
CLINICAL IMPLICATIONS AND IMPLEMENTATION OF
RECOMMENDATIONS
This guideline is aimed primarily at rheumatologists but also at
a broad spectrum of other healthcare providers and reflect ‘‘best
practice’’ for patients with inflammatory arthritis.
Although the greater CV risk is increasingly acknowledged,
limited attention is paid to detecting and managing CV
comorbid conditions such as hypertension and dyslipidaemia.
Early identification, adequate CV risk management and ongoing
monitoring of risk factors are mandatory to reduce the (excess)
CV risk. The first principle of management is to assess and
control all components of total CV risk. This includes
appropriate evidenced-based advice with regard to smoking,
physical activity, nutrition, weight and blood pressure.
Cardioprotective treatment should be initiated when the
estimated 10-year CV risk is above the risk threshold for each
country, whether 10% or 20%. Finally, the clear relationship
between disease activity and CV disease underlines the
importance of tight disease control. Overall, this document
provides evidence-based and expert opinion-based recommenda-
tions on the steps that should be followed to lower the CV risk
in patients with inflammatory arthritis.
EXAMPLE
Figure 1 shows the 10-year risk of fatal cardiovascular disease in
patients at high risk. Consider a 63-year-old female patient with
RA with total cholesterol of 7.5 mmol/l and HDL-c of
1.5 mmol/l, a systolic blood pressure of 165 mm Hg, who
smokes. In this instance, according to the SCORE model, the 10-
year CV risk is 7% risk of fatal CV disease within 10 years. If
this patient is IgM-RF positive and has disease duration of more
than 10 years, we need to multiply this risk by 1.5, resulting in a
10.5% chance of fatal CV disease within 10 years. According to
current ‘‘Dutch’’ guidelines, treatment with statins and/or
hypertensive agents will be started when the CV risk score is
above 10%, provided that the systolic blood pressure is
>140 mm Hg and/or the LDL-c is >2.5 mmol/l. Hence,
treatment with a statin and an antihypertensive agent will be
started.
Figure 1 Ten-year risk of fatal cardiovascular disease (CVD) in patients at high CVD risk. Chart based on total cholesterol:high-density lipoprotein
(HDL) cholesterol. Reproduced from Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the
SCORE project. Eur Heart J 2003;24(11):987–1003, by permission of Oxford University Press.
Recommendations
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